Cure of Helicobacter pylori infection induces remission in most patients with gastric mucosa-associated lymphoid tissue lymphoma that is associated with these bacteria.
Dr Thomas Wündisch and colleagues determined the long-term outcomes of these patients in a prospective multicenter trial, and investigated whether they developed second cancers or had histologic residual disease.
The research team followed 120 patients with stage EI1 gastric mucosa-associated lymphoid tissue lymphoma for a median of 122 months after H. pylori eradication.
|80% achieved complete remission|
Remission was determined by histology analysis and development of second cancers was documented.
Of the patients, 80% achieved complete remission from gastric mucosa-associated lymphoid tissue lymphoma, and 80% of those remained disease free.
Estimated mean survival time in the Kaplan–Meier analysis was 147 months.
Of the patients that achieved complete remission, the team found that 17% had histologic residual disease after a median of 32 months.
The team observed that disease did not progress in any of these patients, and all but 1 achieved a second complete remission.
The researchers revealed a significantly higher incidence of gastric cancer or non-Hodgkin lymphoma in the 96 patients that achieved a complete remission, compared with the general German population.
Dr Wündisch's team commented, "Cure of H. pylori infection leads to continuous complete remission in most patients with H. pylori–associated gastric mucosa-associated lymphoid tissue lymphoma."
"Patients are at risk for development of secondary cancers."